Market Overview:
The global multiple sclerosis drugs treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of multiple sclerosis, rising awareness about available treatments, and technological advancements in the field of MS drugs. The global multiple sclerosis drugs treatment market is segmented on the basis of type into interferon, immunomodulator, and immunosuppressant. The interferon segment is expected to dominate the market during the forecast period owing to its high efficacy and safety profile. On the basis of application, this market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and other applications such as clinics and research institutes. The hospital pharmacy segment dominates this market due to increased use of MS drugs for treating patients admitted in hospitals for various reasons such as surgery or an accident etcetera.
Product Definition:
The term "multiple sclerosis drugs treatment" refers to the various medications used to treat the symptoms of multiple sclerosis (MS). These drugs can help reduce inflammation, improve nerve function, and protect against damage caused by MS. They may also help slow the progression of MS.
Interferon:
Interferon is a type of protein that is made in the body and when injected into the body, it helps fight diseases such as Multiple Sclerosis (MS). Interferons are used to treat MS by helping myelination, which is the process through which the brain & spinal cord get protected from inflammation. The drug works by reducing attacks as well as improving long-term disability associated with multiple sclerosis. It also helps reduce relapses and side effects of multiple sclerosis.
Immunomodulator:
An immunomodulator is a drug that modulates the immune system in some way. Immunomodulators are used to treat relapsing-remitting multiple sclerosis, as well as secondary progressive multiple sclerosis. They may also be used to prevent the occurrence of attacks in people who are at risk of developing multiple sclerosis (primarily patients with HIV infection).
Application Insights:
Based on application, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. The hospital pharmacies dominated the overall industry in terms of revenue in 2017. This can be attributed to factors such as presence of a large patient base with multiple sclerosis and increasing prevalence of demyelinating diseases globally. Hospital pharmacies offer round-the-clock services whereas other pharmacies may operate during daytime hours only.
The online pharma systms are widely adopted by patients preferring convenience over visiting their local pharmacists for routine medication refills or checkups with their doctors¢â‚¬â„¢ offices or hospitals.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives, and high disease prevalence are some of the major factors contributing to its growth. In 2014, Merck & Co., Inc. introduced a new drug for multiple sclerosis named as Sotagliflozin/Onglyza combo pill that is approved by U.
Asia Pacific is expected to be the fastest growing region over the forecast period owing to increasing healthcare expenditure.
Major companies include but are not limited to Novartis AG; Pfizer Inc.
Growth Factors:
- Increasing incidence of multiple sclerosis (MS)
- Growing awareness about MS and its treatment options
- Rising demand for better and more effective therapies for MS
- Availability of government funding for MS research and development
- Technological advancements in the field of MS drugs treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Multiple Sclerosis Drugs Treatment Market Research Report
By Type
Interferon, Immunomodulator, Immunosuppressant
By Application
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other
By Companies
Pfizer, Roche, Biogen, Teva Pharmaceutical, Merck, Novartis, Bayer, Sanofi, Acorda Therapeutics, Questcor Pharmaceuticals, AbbVie, Opexa Therapeutics, Genzyme Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
139
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global Multiple Sclerosis Drugs Treatment Market Report Segments:
The global Multiple Sclerosis Drugs Treatment market is segmented on the basis of:
Types
Interferon, Immunomodulator, Immunosuppressant
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Roche
- Biogen
- Teva Pharmaceutical
- Merck
- Novartis
- Bayer
- Sanofi
- Acorda Therapeutics
- Questcor Pharmaceuticals
- AbbVie
- Opexa Therapeutics
- Genzyme Corporation
Highlights of The Multiple Sclerosis Drugs Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Interferon
- Immunomodulator
- Immunosuppressant
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Multiple Sclerosis Drugs Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Multiple sclerosis drugs treatment is the use of medications to help control the symptoms of multiple sclerosis. These medications can help reduce inflammation and improve nerve function.
Some of the major players in the multiple sclerosis drugs treatment market are Pfizer, Roche, Biogen, Teva Pharmaceutical, Merck, Novartis, Bayer, Sanofi, Acorda Therapeutics, Questcor Pharmaceuticals, AbbVie, Opexa Therapeutics, Genzyme Corporation.
The multiple sclerosis drugs treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Multiple Sclerosis Drugs Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Multiple Sclerosis Drugs Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Multiple Sclerosis Drugs Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Multiple Sclerosis Drugs Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Multiple Sclerosis Drugs Treatment Market Size & Forecast, 2018-2028
4.5.1 Multiple Sclerosis Drugs Treatment Market Size and Y-o-Y Growth
4.5.2 Multiple Sclerosis Drugs Treatment Market Absolute $ Opportunity
Chapter 5 Global Multiple Sclerosis Drugs Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Multiple Sclerosis Drugs Treatment Market Size Forecast by Type
5.2.1 Interferon
5.2.2 Immunomodulator
5.2.3 Immunosuppressant
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Multiple Sclerosis Drugs Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Multiple Sclerosis Drugs Treatment Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Retail Pharmacy
6.2.3 Online Pharmacy
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Multiple Sclerosis Drugs Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Multiple Sclerosis Drugs Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Multiple Sclerosis Drugs Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Multiple Sclerosis Drugs Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Multiple Sclerosis Drugs Treatment Market Size Forecast by Type
9.6.1 Interferon
9.6.2 Immunomodulator
9.6.3 Immunosuppressant
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Multiple Sclerosis Drugs Treatment Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Retail Pharmacy
9.10.3 Online Pharmacy
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Multiple Sclerosis Drugs Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Multiple Sclerosis Drugs Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Multiple Sclerosis Drugs Treatment Market Size Forecast by Type
10.6.1 Interferon
10.6.2 Immunomodulator
10.6.3 Immunosuppressant
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Multiple Sclerosis Drugs Treatment Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Retail Pharmacy
10.10.3 Online Pharmacy
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Multiple Sclerosis Drugs Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Multiple Sclerosis Drugs Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Multiple Sclerosis Drugs Treatment Market Size Forecast by Type
11.6.1 Interferon
11.6.2 Immunomodulator
11.6.3 Immunosuppressant
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Multiple Sclerosis Drugs Treatment Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Retail Pharmacy
11.10.3 Online Pharmacy
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Multiple Sclerosis Drugs Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Multiple Sclerosis Drugs Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Multiple Sclerosis Drugs Treatment Market Size Forecast by Type
12.6.1 Interferon
12.6.2 Immunomodulator
12.6.3 Immunosuppressant
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Multiple Sclerosis Drugs Treatment Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Retail Pharmacy
12.10.3 Online Pharmacy
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Multiple Sclerosis Drugs Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Multiple Sclerosis Drugs Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Multiple Sclerosis Drugs Treatment Market Size Forecast by Type
13.6.1 Interferon
13.6.2 Immunomodulator
13.6.3 Immunosuppressant
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Multiple Sclerosis Drugs Treatment Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Retail Pharmacy
13.10.3 Online Pharmacy
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Multiple Sclerosis Drugs Treatment Market: Competitive Dashboard
14.2 Global Multiple Sclerosis Drugs Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Roche
14.3.3 Biogen
14.3.4 Teva Pharmaceutical
14.3.5 Merck
14.3.6 Novartis
14.3.7 Bayer
14.3.8 Sanofi
14.3.9 Acorda Therapeutics
14.3.10 Questcor Pharmaceuticals
14.3.11 AbbVie
14.3.12 Opexa Therapeutics
14.3.13 Genzyme Corporation
